A 68-year-old man with hepatocellular carcinoma complicated by erythrocytosis showed an increased plasma level of immunoreactive erythropoietin (EPO). Northern blot analysis and RT-PCR(reverse transcriptase and polymerase chain reaction) of EPOmRNA extracted from a surgical specimen indicated high expression of EPOmRNAin the tumor tissue. Histological and immunocytochemical examination showedthat the tumor wasa hepatocellular carcinomawith predominant immunostaining for EPO. The erythrocytosis improved and the high serum EPO level decreased after resection of the tumor. This is the first demonstration of EPOmRNA expression in hepatocellular carcinoma tissue by RT-PCR.
Introduction Erythropoietin
(EPO) is a glycoprotein hormone that is correlated with differentiation and proliferation of erythroid cells. EPO is mainly synthesized in the liver in the fetal period and in the kidney after birth. Its sites of production are thought to be peritubular cells in the kidney and bile duct epithelium in the liver (1, 2) . Hypoxia and anemia stimulate EPO synthesis and increase its serum level (3, 4) . Erythrocytosis associated with malignant tumors is closely related to a high level of serum EPO. The incidence of hepatocellular carcinomas producing EPOis not high, and the mechanism of production of EPOby tumorcells is still uncertain. Here, we report a case of hepatocellular carcinoma producing EPO associated with erythrocytosis. Studies on the expression of EPOmRNA in the tumor tissue and normal liver tissue of the patient by northern blot analysis and reverse transcriptase and polymerasechain reaction (RT-PCR)are presented, as well as demonstration of the presence of the EPO protein by immunostaining.
Patient and Method
Patient A 68-year-old Japanese man was admitted to our hospital with abdominal pain. On physical examination, his liver was palpable for 8 cm in the midclavicular line. An initial blood examination showedhigh levels of tumor markers such as afetoprotein (AFP) 34,640 ng/ml (normal range <20 ng/ml), and raised levels oftransaminases such as GOT(76 IU/1). Tests for hepatitis virus markers all gave negative results. His ICG (15 min) was 14.9%, RBC 693xlO6, Hb 20.4 g/dl, Ht62.0%, WBC 3,800, thrombocyte 17.6xlO4, serum Fe 58 jig/ml, and ferritin 78 ng/ml. His serum EPOimmunoreactivity was 53.0 mU/ml (normal range 8-36 mU/ml), suggesting that the tumor cells were producing EPO. A bone marrow specimen showed mild erythrocytosis, and chromosomal analysis revealed normal 46-XY. Abdominal echo and computerized tomographic (CT) examination revealed the presence of a massive lesion in the right lobe S6_7, which showed irregular enhancement ( Fig. 1 ). Angiography indicated a hypervascular hepatic mass in S6_7 (Fig. 2) . By examination of a biopsy specimen, the tumor was identified as a liver cell carcinoma (Edmondson III). The tumor was excised by surgery. Although 520 ml of blood was lost during surgery, blood transfusion was not necessary during operation. By right lobectomy, a tumor of 70x60x55 mmwas NuSieve agarose (3%) gel (FMC BioProducts, Rockland, ME).
After electrophoresis, the gel was stained with ethidium bro- 
Immunohistochemical staining
Tissues were fixed in 10% formalin and embedded in paraffin. Sections of5 jum thickness were incubated with antiserum to EPO (6) at dilutions of 1:100 to 1:500, and stained by the avidin-biotin peroxidase complex method.
Results

RT-PCR
The 305-bp regions of B-actin CDNAin normal peripheral blood, tumor tissue and normal liver tissue were amplified equally (Fig. 3A) . A strong band of 290-bp of amplified EPO CDNAwas detected in tumor CDNAand a weak band in normal tissue of CDNA (Fig. 3B ).
Northern blot analysis Studies showed that the EPOprobe hybridized to an RNAof 1.2 kb in mRNA extracted from tumor tissue, but not from normal liver tissue (Fig. 4) .
Immunohistochemical staining
Strong cytoplasmic stainings were observed with antibodies to EPO ( not in normal liver tissue (Fig. 5) .
Clinical course Erythrocytosis and high levels of serum EPOand AFP improved after resection of the tumor (Fig. 6 ).
Discussion
The complication of erythrocytosis has been observed in malignant tumors such as renal cancers, hepatocellular carcinomas, and cerebral meningioma. In patients with hepatocellular carcinoma, the incidence of erythrocytosis is 3 to 12% (7).
However,there have been few studies on gene expression or protein synthesis ofEPOin tumor tissues (8-10). In the present case, erythrocytosis with a high serum level of EPOimmunoreactivity was observed at the time of admission. Moreover, we confirm higher expression of EPOmRNA in tumor tissue than in normal tissue in surgical specimens of the liver by RT-PCR and northern blot analysis. Immunohistochemical staining also revealed the production of EPOprotein in the tumor tissue, but not in normal liver tissue. EPOmRNAis considered to reflect the number of cells producing EPO in the kidney (1 1 
